All In Biotech

Free tool

FAERS Monitor: Omlonti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215092 or its brand name (Omlonti, Omidenepag Isopropyl). Reports on generic versions are filed under their own applications.

Reports

66

Serious

64

97% of reports

Hospitalization

10

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cataract20
  • contraindicated product administered9
  • intercepted product prescribing error6
  • cystoid macular oedema5
  • intraocular pressure increased5
  • anaphylactic reaction4
  • glaucoma4
  • macular oedema4
  • uveitis4
  • vision blurred4
  • ocular hyperaemia3
  • refraction disorder3
  • cataract operation2
  • corneal erosion2
  • corneal opacity2

Reports by year received

View as table
YearReports
20221
202312
202421
202518
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
refraction disorderSignal33334.51097.16,870
intercepted product prescribing errorSignal61450.0674.87,267
corneal erosion21188.1302.71,329
cystoid macular oedemaSignal5848.0364.63,416
corneal opacity2467.7119.4522
macular oedemaSignal4227.688.0690
intraocular pressure increasedSignal5124.753.7496
cataract operation2107.427.4118
cataractSignal20107.174.32,002
contraindicated product administeredSignal994.851.6745
uveitisSignal494.036.4281
glaucomaSignal466.225.6196
anaphylactic reactionSignal423.18.964
ocular hyperaemiaSignal320.16.737
vision blurredSignal49.33.622

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.